The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Christopher Manley and Kristen Scully Manley join Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CHRISTOPHER MANLEY and KRISTEN SCULLY MANLEY joined Fox Chase Cancer Center.

Christopher Manley will serve as the director of interventional pulmonology in the Department of Medicine, and Kristen Scully Manley will serve as a hospitalist in the department of medicine.

“Dr. Manley’s expertise in pulmonary medicine makes him the perfect candidate for our new director of interventional pulmonology,” said David Weinberg, chair of the department of medicine.

He will join Fox Chase after finishing his interventional pulmonology fellowship at Beth Israel Deaconess Medical Center and Massachusetts General Hospital this summer.

Scully Manley most recently served as a member of the hospitalist team in the division of general medicine and primary care at Beth Israel Deaconess, where she was honored as Clinician of the Year in 2015.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account